1. Home
  2. FLNT vs AARD Comparison

FLNT vs AARD Comparison

Compare FLNT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fluent Inc.

FLNT

Fluent Inc.

HOLD

Current Price

$3.39

Market Cap

90.9M

ML Signal

HOLD

Logo Aardvark Therapeutics Inc.

AARD

Aardvark Therapeutics Inc.

HOLD

Current Price

$4.87

Market Cap

85.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLNT
AARD
Founded
2010
2017
Country
United States
United States
Employees
N/A
40
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
90.9M
85.7M
IPO Year
2009
N/A

Fundamental Metrics

Financial Performance
Metric
FLNT
AARD
Price
$3.39
$4.87
Analyst Decision
Hold
Buy
Analyst Count
1
9
Target Price
$3.50
$15.29
AVG Volume (30 Days)
220.9K
123.0K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
41.67
N/A
EPS
N/A
N/A
Revenue
$208,764,000.00
N/A
Revenue This Year
$5.89
N/A
Revenue Next Year
$12.62
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$3.35
52 Week High
$4.15
$17.94

Technical Indicators

Market Signals
Indicator
FLNT
AARD
Relative Strength Index (RSI) 69.96 61.92
Support Level $2.95 $4.81
Resistance Level $3.57 $5.83
Average True Range (ATR) 0.30 0.34
MACD 0.15 0.15
Stochastic Oscillator 94.57 83.43

Price Performance

Historical Comparison
FLNT
AARD

About FLNT Fluent Inc.

Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.

About AARD Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Share on Social Networks: